Recommended Alternative: GLP-1 Receptor Agonist
For a patient experiencing bothersome urinary frequency on Jardiance (empagliflozin) who cannot take metformin due to impaired kidney function, switch to a GLP-1 receptor agonist as the preferred alternative glucose-lowering medication. 1
Rationale for GLP-1 RA Selection
The 2024 ADA/KDIGO consensus algorithm specifically recommends GLP-1 RAs for patients with type 2 diabetes and chronic kidney disease when SGLT2 inhibitors are not tolerated 1. This recommendation prioritizes:
- Cardiovascular risk reduction - GLP-1 RAs reduce CVD events independent of glucose control
- Kidney protection - Evidence suggests they slow CKD progression (22% reduction in composite renal outcomes with liraglutide) 1
- Low hypoglycemia risk - Critical advantage when metformin and SGLT2 inhibitors are unavailable
- Weight loss benefit - Maintains the metabolic advantage you were getting from Jardiance
Why Stop Jardiance
The urinary frequency is a direct consequence of empagliflozin's mechanism - it increases renal glucose excretion, which creates an osmotic diuresis 2. This side effect will not resolve while continuing the medication. Since the patient finds this bothersome enough to warrant a change, and you have effective alternatives available, discontinuation is appropriate.
Alternative Options by Kidney Function Level
If eGFR 30-60 mL/min/1.73 m² (Stage 3 CKD):
First choice: GLP-1 RA (no dose adjustment needed for most agents) 1
Second-line alternatives:
- DPP-4 inhibitors - Linagliptin requires no dose adjustment; sitagliptin, saxagliptin, and alogliptin need adjustment 3
- Basal insulin - Requires dose reduction as eGFR declines but highly effective 3
If eGFR <30 mL/min/1.73 m² (Stage 4-5 CKD):
GLP-1 RA remains preferred for cardio-renal protection 1
Insulin becomes more prominent as kidney function worsens, though doses must be carefully titrated downward 3
Agents to Avoid in This Patient
- Pioglitazone - Not recommended in kidney impairment due to fluid retention risk; contraindicated if any heart failure 3
- Glyburide - Generally not recommended in CKD due to hypoglycemia risk 3
- Metformin - Already excluded (contraindicated if eGFR <30, reassess risk/benefit if eGFR <45) 1
Common Pitfalls
Don't simply reduce the Jardiance dose - The urinary frequency is mechanism-based and dose-related but will persist at any therapeutic dose. The FDA label shows empagliflozin's glucose-lowering efficacy decreases substantially as kidney function declines anyway 2.
Don't overlook cardiovascular protection - This patient was on an SGLT2 inhibitor, suggesting either established cardiovascular disease or high risk. GLP-1 RAs provide comparable cardiovascular benefits, making them the logical replacement 1.
Monitor kidney function closely during transition - GLP-1 RAs have been shown to slow CKD progression, but you should check eGFR 2-4 weeks after initiation to ensure stability 1.